Actieve functies van Lu Alleruzzo
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Immunophotonics, Inc.
 Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Directeur/Bestuurslid | 01-01-2009 | - |
| Algemeen Directeur | - | - | |
| Oprichter | 01-01-2009 | - | |
| Operationeel Directeur | 01-01-2009 | - | |
| President | 01-01-2009 | - |
Loopbaan van Lu Alleruzzo
Opleiding van Lu Alleruzzo
| University of Missouri | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 3 |
Operationeel
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
| Chief Operating Officer | 1 |
Sectoraal
| Health Technology | 2 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Health Technology |
- Beurs
- Insiders
- Lu Alleruzzo
- Ervaring
